课题基金 / 基金详情

Regulation of the brain-specific cholesterol hydroxylase Cyp46A1 as a novel approach for the treatment of prion diseases

Regulation of the brain-specific cholesterol hydroxylase Cyp46A1 as a novel approach for the treatment of prion diseases
调节大脑特异性胆固醇羟化酶 Cyp46A1 作为治疗朊病毒疾病的新方法
批准号：
454456
负责人：
Ali Tahir
金额：
$3.28万
依托单位：
University of Calgary
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-10-01 至 2022-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=454456&lang=en
关键词：
Brain Cholesterol Metabolism Cellular Models Of Prion Diseases Cholesterol 24-Hydroxylase (Cyp46a1) Cyp46a1 Activator (Efavirenz) Fda-Approved Repurposed Drug (Efavirenz) Human Prion Diseases Mouse Models Of Human Prion Diseases Neurodegenerative D

项目摘要

项目成果

Ali Tahir的其他基金

相关文献

中文摘要
翻译
朊病毒疾病是影响人类和动物的传染性和致命的神经退行性疾病。克雅氏病是人类最常见的朊病毒疾病。动物朊病毒疾病包括绵羊/山羊痒病和疯牛病
英文摘要
Prion diseases are infectious and fatal neurodegenerative disorders that affect humans and animals. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. Animal prion diseases include scrapie in sheep/goat and mad cow disease, which has
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Brain-specific enzyme cholesterol 24-hydroxylase (Cyp46A1) as a novel therapeutic target in human prion diseases
  • 批准号：
    440680
  • 项目类别：
    Fellowship Programs
  • 资助金额：
    $9.83万
  • 财政年份：
    2020
  • 负责人：
    Ali Tahir
  • 依托单位：
    University of Calgary
Cyp46A1 as a novel therapeutic target in prion diseases
  • 批准号：
    436100
  • 项目类别：
    Fellowship Programs
  • 资助金额：
    $10.2万
  • 财政年份：
    2020
  • 负责人：
    Ali Tahir
  • 依托单位：
    University of Calgary